Nurix Therapeutics, Inc. has grown revenue −16% a year over three years and 10.0% a year over five. Revenue growth, 3-year annual rate: −16% (Biotechnology median +17%). Revenue growth, 5-year rate: +10.0%, growth has slowed since the five-year average. Years of annual history on file: 7, FY2019 to FY2025, as filed.

NRIXNurix Therapeutics, Inc.

Healthcare

$22.36+165% 1Y

$22.36

$8.2452 weeks$27.79

Is it growing?

Watch

Growth is fading: revenue shrinking (−58% year on year) and operating margin narrowing (−730.0 points).

2 to watch, 1 without data

Revenue trend−58% in a year

Trailing-twelve-month revenue vs a year earlier, from the company's own filings. Five-year pace: +10% a year.

Margin direction−730.0 points operating

Trailing-twelve-month operating margin, -1072.7% now against -342.7% a year earlier.

All from SEC EDGAR, as of May 31, 2026.

Where this answer is blind. These are trailing numbers from the filings, not forecasts: an acquisition or a one-off year can flatter them, so check the quarters.

Is NRIX growing?

Nurix Therapeutics, Inc. has grown revenue −16% a year over three years and 10.0% a year over five.

−16%

Revenue growth, 3-year annual rate · Biotechnology median +17% · shrinking · compounded from trailing twelve-month revenue

Revenue growth, 5-year rate: +10.0%
Revenue growth, 5-year rate · −16% over three · growth has slowed since the five-year average
Years of annual history on file: 7
Years of annual history on file · FY2019 to FY2025, as filed

Details›